Auxilium Pharmaceuticals (NASDAQ: AUXL) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Institutional & Insider Ownership

58.0% of Syros Pharmaceuticals shares are owned by institutional investors. 33.6% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Auxilium Pharmaceuticals and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%
Syros Pharmaceuticals N/A -62.01% -55.65%

Valuation and Earnings

This table compares Auxilium Pharmaceuticals and Syros Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Auxilium Pharmaceuticals N/A N/A N/A ($3.27) -11.15
Syros Pharmaceuticals $320,000.00 853.93 -$47.74 million ($1.74) -5.97

Auxilium Pharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Auxilium Pharmaceuticals and Syros Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auxilium Pharmaceuticals 0 0 0 0 N/A
Syros Pharmaceuticals 0 2 6 0 2.75

Syros Pharmaceuticals has a consensus price target of $23.83, suggesting a potential upside of 129.40%. Given Syros Pharmaceuticals’ higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Auxilium Pharmaceuticals.

Summary

Syros Pharmaceuticals beats Auxilium Pharmaceuticals on 9 of the 10 factors compared between the two stocks.

Auxilium Pharmaceuticals Company Profile

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive News & Ratings for Auxilium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.